Autres langues Jazz Pharmaceuticals plc

Actions

JAZZ

IE00B4Q5ZN47

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
107,4 ^USD	-0,82 %		-1,68 %	-12,66 %

02/04	Jazz Pharmaceuticals complète sa demande de licence auprès de la FDA pour le traitement du cancer des voies biliaires	MT
02/04	Jazz Pharmaceuticals complète la demande de licence de produit biologique pour le zanidatamab dans le traitement du cancer métastatique des voies biliaires HER2-positif précédemment traité	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Jazz Pharmaceuticals to Present Data across Growing Oncology Pipeline and Portfolio at ASCO 2024	25/04
The PharmaMar Group presents financial results for the first quarter of 2024	24/04
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024	17/04
Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	02/04
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	02/04
Jazz Pharmaceuticals : Zanidatamab R&D Day	19/03
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024	12/03
Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)	07/03
Jazz Pharmaceuticals : Corporate Overview	01/03
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016.	28/02
Jazz: Q4 Earnings Snapshot	28/02
Jazz Pharmaceuticals Swings to Q4 Non-GAAP Earnings, Revenue Rises; 2024 Guidance Set, Shares Down After Hours	28/02
(JAZZ) JAZZ PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $18.15 - $19.35	28/02
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue $4B-$4.2B	28/02
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q4 EPS $5.02, vs. Street Est of $5.18	28/02
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q4 Revenue $1.01B, vs. Street Est of $1.01B	28/02
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance	28/02
Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024	28/02
Jazz Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Jazz Pharmaceuticals plc

Actions

JAZZ

IE00B4Q5ZN47

Autres langues

Filtres